ANI Pharmaceuticals, Inc. filings document financial results, operating updates, governance matters, and material events for its Rare Disease, Generics, and Brands businesses. Form 8-K reports furnish earnings releases, preliminary results, guidance updates, Regulation FD investor presentations, and corporate changes such as independent auditor matters.
ANI proxy filings cover shareholder voting items, board governance, executive compensation, equity awards, and related governance disclosures. The filing record also provides formal context for product and business risks tied to biopharmaceutical development, FDA-regulated generic launches, branded products, commercialization, manufacturing, and capital actions.
ANIP affiliate submitted a Rule 144 notice to sell 55,000 shares of Common Stock on Nasdaq. The filing lists four planned issuances/allocations tied to performance shares and restricted stock dated 02/11/2026, 02/14/2026, and 03/07/2026. The cover line shows 55,000 shares, a value field of $4,266,563.58, and a reference figure of 22,734,618.
Patrick Walsh submitted a Form 144 notice to sell 3,973 shares of Common Stock. The filing lists the securities as restricted stock with an original grant date of 05/21/2025. The filing also reports that 6,000 shares were sold on 03/03/2026 for $445,390.20.
ANI Pharmaceuticals, Inc. reported strong results for the quarter ended March 31, 2026, with net revenues of $237.5 million, up from $197.1 million a year earlier. Net income rose to $29.5 million versus $15.7 million, driving diluted earnings per share to $1.28, compared with $0.69 in the prior-year period.
Growth was driven by Rare Disease and Brands, where net revenues increased to $128.2 million from $94.1 million, including $75.1 million from Cortrophin Gel and $19.3 million from ILUVIEN and YUTIQ. Generics and Other net revenues increased to $109.2 million from $103.0 million.
Operating income improved to $38.9 million from $26.2 million, helped by higher sales and a favorable contingent consideration fair value adjustment. Cash and cash equivalents grew to $311.2 million from $285.6 million at year-end, supported by $58.4 million of cash provided by operating activities, while total liabilities decreased modestly to $859.7 million from $899.7 million.
ANI Pharmaceuticals reported strong first quarter 2026 growth and raised its full-year outlook. Net revenues reached $237.5 million, up 20.5% year-over-year, led by Rare Disease products and Generics. Cortrophin Gel net revenues were $75.1 million, a 42.1% increase, and ILUVIEN net revenues were $19.3 million, up 19.5%, both mainly driven by higher volume.
GAAP net income available to common shareholders rose to $29.5 million, with diluted GAAP EPS of $1.28, while adjusted non-GAAP diluted EPS was $2.05. Adjusted non-GAAP EBITDA grew 24.1% to $63.0 million. The company now guides 2026 total net revenue to $1.08–$1.14 billion and adjusted non-GAAP EBITDA to $285–$300 million, and expects adjusted non-GAAP diluted EPS of $9.19–$9.69.
ANI reaffirmed 2026 Cortrophin Gel net revenue guidance of $540–$575 million and ILUVIEN guidance of $78–$83 million. The board also authorized a $100 million share repurchase program through May 2029, to be funded with the company’s cash resources.
ANI Pharmaceuticals senior vice president Meredith Cook sold a small block of company stock in a pre-planned trade. Cook executed an open-market sale of 500 shares of ANI Pharmaceuticals common stock at $77.95 per share. After this transaction, she continues to hold 78,890 shares directly, indicating she retains the vast majority of her stake. The sale was carried out under a Rule 10b5-1 trading plan adopted in advance, which means the trade was pre-scheduled rather than timed discretionarily.
ANI Pharmaceuticals, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 21, 2026. Holders of 22,750,198 shares of Common Stock and 10,864 shares of Class C Special Stock as of March 23, 2026 can vote one vote per share.
Stockholders will elect seven directors, ratify Ernst & Young LLP as auditor for 2026, cast advisory votes on executive compensation and its future frequency, and approve an Amended and Restated 2022 Stock Incentive Plan. The proxy highlights record 2025 net revenues of $883.4 million, up 43.8%, and adjusted non‑GAAP EBITDA of $229.8 million, up 47.3%, driven by strong Rare Disease and Generics performance.
ANI Pharmaceuticals changed its independent auditor. On April 1, 2026, the company dismissed EisnerAmper LLP as its independent registered public accounting firm and, on the same date, the Audit and Finance Committee approved the appointment of Ernst & Young LLP for the fiscal year ending December 31, 2026.
The company states that EisnerAmper’s audit reports for the years ended December 31, 2025 and 2024 contained no adverse opinions, disclaimers, or qualifications. It also reports no disagreements or reportable events with EisnerAmper during those periods, and has filed EisnerAmper’s response letter as an exhibit.
ANI Pharmaceuticals Inc ownership disclosure: The Vanguard Group amended its Schedule 13G to report it beneficially owns 0 shares of ANI Pharmaceuticals Inc common stock, representing 0%. The filing states an internal realignment on January 12, 2026 led certain Vanguard subsidiaries to report separately under SEC Release No. 34-39538.
ANI Pharmaceuticals senior executive sells part of stake
ANI Pharmaceuticals’ SVP, Head – Established Brands, Thomas Andrew Rowland, reported an open-market sale of 4,772 shares of common stock at an average price of $74.91 per share. After this transaction, he directly holds 38,730 shares, indicating a partial sale while retaining a significant remaining position.